Ranok Therapeutics Co. Ltd.-Media

Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMPTM Protein Degrader

- Study will evaluate the first protein degrader developed using Ranok’s innovative CHAMPTM technology in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL)

15 February 2022

Ranok Therapeutics to Present at BMO Biopharma Spotlight Series on Protein Degraders and Other Next Gen Technologies

- CSO Kevin Foley to highlight FDA IND clearance for Ranok’s first clinical program, RNK05047, that was developed using the company’s innovative CHAMPTM technology platform

24 January 2022

Ranok Therapeutics Announces U.S. FDA Clearance to proceed with its first-in-human trial of RNK05047 in patients with advanced solid tumor cancers and lymphomas (CHAMP-1)

- An important milestone for the first protein degrader developed using Ranok’s innovative CHAMPTM technology, with clinical enrollment expected to begin in the first half of 2022

了解更多请点击这里 >

29 November 2021

Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation

- Proposed research will apply Ranok’s innovative CHAMPTM technology to a selected cancer drug target

20 September 2021

Ranok Therapeutics to Present its CHAMPTM Platform at 19th Annual Discovery on Target Conference

- Targeted protein degradation a key topic at leading annual pharmaceutical industry event on novel drug targets and technologies

BioCentury: Back to School preview, plus Pfizer eats Trillium: a BioCentury podcast

- The editors discuss Hangzhou-based Ranok Therapeutics Co. Ltd., a protein degradation company testing a differentiated, chaperone-based approach

BioCentury: The TAC universe grows beyond PROTACs

- On the heels of success using the proteasome to degrade protein targets, a growing crop of companies are turning to autophagy to destroy a broader array of disease-driving substrates

Ranok Therapeutics Secures $40 Million Series B Financing to Advance its Innovative Targeted Protein Degradation Pipeline

– Financing will enable Ranok’s first cancer therapeutic to progress into the clinic along with continued development of its proprietary CHAMPTM tumor-targeted protein degrader platform

了解更多请点击这里 >

BioCentury: Ranok: a chaperone-based approach to targeted degradation

- Emerging company profile: Ranok has raised $40M to test whether alternative to PROTACs could have safety, dosing advantages

Endpoints News: A transpacific biotech rushes toward the clinic with a twist on classic protein degraders

- The protein degradation space has erupted in the last few years, with investors goggling at the idea of eliminating problematic proteins via the body’s natural garbage disposal system

Fierce Biotech: The CHAMP? Ranok raises $40M to show it can knockout other protein degrader technologies

- Add another biotech to the list of protein degrader startups

12 October 2023

Ranok Therapeutics to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

- CSO Kevin Foley to highlight application of company’s innovative CHAMPâ technology to target ERK5, an emerging cancer target

11 March 2024

Ranok Therapeutics Expands Clinical Testing of CHAMPâ BRD4 Protein Degrader RNK05047 to China

-- Study follows ongoing Phase 1 trial in U.S. and will enroll patients in China to evaluate the first protein degrader developed using Ranok’s innovative CHAMPâ technology

4 April 2024

Ranok Therapeutics to Present at American Association for Cancer Research (AACR) Annual Meeting 2024

--Poster presentations to highlight application of company's innovative CHAMP® technology to important cancer targets including KRAS

7 November 2024

Ranok presentation today Thursday 7 November 2024 on "Chaperone-mediated Protein Degradation (CHAMP): A novel technology for Tumor-targeted Protein Degradation" at the Targeted Protein Degradation MicroSummit (virtual)

Read More >

23 Jun 2024

RANOK PRESENTATION: Our CSO Kevin Foley presented on "Tumor-selective, Chaperone-mediated Targeting of ERK5" at the 2nd International Meeting on ERK5 Signaling at the University of Florence, Italy this week

Ranok Therapeutics Announces Closing of Follow-on Seed Funding Round

– Led by TF Capital, financing will enable further development of Ranok's technology platform and advancement of lead cancer program towards clinic

News

Events & Presentations

Press Releases & Media

ꂃ ꁹ

Ranok Therapeutics

United States
303 Wyman Street, Suite 300
Waltham, MA 02451

China
Floor 4, Building 16
Hexiang Science and Technology Center
Qiantang District, Hangzhou 310020
0571-86630936

Contact Us

Business Inquiries

bd@ranoktherapeutics.com

Careers

jobs@ranoktherapeutics.com

Connect with Ranok

Business Inquiries

bd@ranoktherapeutics.com

Careers

jobs@ranoktherapeutics.com

WELCOME to RANOK THERAPEUTICS. We are pioneering the next generation of targeted protein degradation technology to deliver transformative medicines to patients suffering from cancer and other diseases. Follow us on Twitter to keep updated on our progress...

© 2023 Ranok Therapeutics Co. Ltd.